Capital International Investors Adagene Inc. Transaction History

Capital International Investors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.99 - $3.85 $2.21 Million - $4.28 Million	-1,112,200 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.5 - $8.79 $88,662 - $222,668	-25,332 Reduced 2.23%	1,112,200 $3.97 Million
Q3 2021 Nov 15, 2021	BUY	$12.7 - $20.68 $2.72 Million - $4.43 Million	214,263 Added 23.21%	1,137,532 $16.5 Million
Q1 2021 May 14, 2021	BUY	$17.0 - $29.99 $15.7 Million - $27.7 Million	923,269 New	923,269 $16.6 Million

10.9M

Ticker ADAG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,423,200
Market Cap $123M
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.